[{"symbol": "NUVL", "price": 104.26, "beta": 1.319, "volAvg": 640311, "mktCap": 7580402106, "lastDiv": 0, "range": "55.535-112.88", "changes": -1.9, "companyName": "Nuvalent, Inc.", "currency": "USD", "cik": "0001861560", "isin": "US6707031075", "cusip": "670703107", "exchange": "NASDAQ Global Select", "exchangeShortName": "NASDAQ", "industry": "Biotechnology", "website": "https://www.nuvalent.com", "description": "Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; and NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under Phase I/II clinical trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.", "ceo": "James R. Porter", "sector": "Healthcare", "country": "US", "fullTimeEmployees": "162", "phone": "857 357 7000", "address": "One Broadway", "city": "Cambridge", "state": "MA", "zip": "02142", "dcfDiff": 102.06616, "dcf": 2.193844207863392, "image": "https://images.financialmodelingprep.com/symbol/NUVL.png", "ipoDate": "2021-07-29", "defaultImage": false, "isEtf": false, "isActivelyTrading": true, "isAdr": false, "isFund": false}]